GENETIC EPIDEMIOLOGIC STUDY OF PROSTATE CANCER

我们正在进行一项研究，以评估 前列腺癌。特别是，我们正在研究兄弟在哪里 至少有一个人患有前列腺癌，以研究其潜在的 遗传因素与疾病的关系。兄弟俩会 主要通过CASE的登记被招募到这项研究中 西部储备大学、克利夫兰临床基金会、亨利 福特健康系统、大都会健康医疗中心和大学 克利夫兰医院。更具体地说，我们正在联系那些 在这些机构被诊断出患有前列腺癌 如果他们有兄弟，他们是否愿意加入我们的 学习。由于我们关注的是遗传因素，在这个时候我们 只联系那些70岁或更年轻的男性 确诊(他们的兄弟可以是任何年龄的人)。我们在采血 以及关于他们的健康、习惯和 节食。我们将从血液中提取DNA，然后利用这些信息 看看那些看似可能导致前列腺癌的基因， 根据目前的科学证据。特别是我们会研究 患有前列腺癌的兄弟是否会遗传某些形式的 基因的频率比预期的要高，以及这种形式的 这些基因与前列腺癌的侵袭性有关。 如果是这样的话，这意味着这些基因在发育和/或 前列腺癌的侵袭性。这项研究提供的信息 将有助于为男性提供关于他们的风险的额外知识 前列腺癌，以及，如果他们已经患病，基因如何 影响他们对治疗的反应。)

We are undertaking a study to evaluate the genetic basis of prostate cancer. In particular, we are studying brothers where at least one has prostate cancer in order to investigate the potential relation between genetic factors and their disease. The brothers will be primarily recruited into the study through registries at Case Western Reserve University, the Cleveland Clinic Foundation, the Henry Ford Health System, MetroHealth Medical Center, and University Hospitals of Cleveland. More specifically, we are contacting men who have been diagnosed with prostate cancer at these institutions to see if they have brothers and whether they would be willing to join our study. Since we are focusing on genetic factors, at this time we are only contacting those men who were aged 70 or younger when they were diagnosed (their brothers can be any age). We are collecting blood from the men, as well as basic information on their health, habits and diet. From the blood we will get DNA, and then use this information to look at those genes that plausibly could lead to prostate cancer, based on current scientific evidence. In particular, we will study whether brothers who have prostate cancer inherit certain forms of the genes more often than expected by chance, and whether such forms of these genes are associated with the aggressiveness of prostate cancer. If so, this implicates such genes in the development and/or aggressiveness of prostate cancer. The information from this study will help provide men with additional knowledge about their risk of prostate cancer and, if they are already diseased, how genes might influence their response to treatment. )